| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2020. Refer to TA664: Liraglutide for managing overweight and obesity for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | liraglutide (Saxenda®) | |
| Formulation | 6 mg/ml solution for injection | |
| Reference number | 1799 | |
| Indication | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obese), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight |
|
| Company | Novo Nordisk Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Date of issue | 15/07/2015 | |
| NICE guidance | ||
| Commercial arrangement | PAS | |